Abivax Announces Results of May 30, 2024 General Meeting

On June 4, 2024, Abivax SA, a clinical-stage biotechnology firm listed on Euronext Paris and Nasdaq under the ticker ABVX, convened its ordinary and extraordinary general meeting of shareholders on May 30, 2024. The meeting, chaired by CEO and Chairman of the Board of Directors, Marc de Garidel, saw the adoption of all proposed resolutions.

Key approvals included the financial statements for the 2023 fiscal year and the compensation policy for the Chairman, Chief Executive Officer, and Board members. Additionally, shareholders granted the Board delegations related to financial transactions. The meeting also ratified the appointments of new Board members: Mr. Troy Ignelzi, Dr. June Lee, and Ms. Camilla Soenderby.

Abivax's principal investigational drug, obefazimod, is an orally administered small molecule that has shown potential in enhancing the expression of microRNA miR-124. Positive data from Phase 2 clinical trials in patients with ulcerative colitis (UC) have led to the commencement of a global Phase 3 clinical trial program known as the ABTECT Program. The first patients were enrolled in the United States in October 2022. Furthermore, a Phase 2b clinical trial for Crohn’s disease is anticipated to start in the third quarter of 2024, and potential combination therapy opportunities in UC are being explored.

Abivax is dedicated to developing treatments that leverage the body's natural regulatory mechanisms to manage chronic inflammatory diseases. The company operates in both France and the United States. Obefazimod (ABX464), their leading drug candidate, is currently undergoing Phase 3 trials for treating moderately to severely active ulcerative colitis.